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104Genome-wide association studies (GWAS) have identiﬁed more than 20 susceptibility loci
for esophageal adenocarcinoma (EA) and Barrett’s esophagus (BE). However, variants
in these loci account for a small fraction of cases of EA and BE. Genetic factors might
interact with environmental factors to affect risk of EA and BE. We aimed to identify
single nucleotide polymorphisms (SNPs) that may modify the associations of body
mass index (BMI), smoking, and gastroesophageal reﬂux disease (GERD), with risks of EA
and BE.105
106
METHODS:107We collected data on single BMI measurements, smoking status, and symptoms of GERD from
2284 patients with EA, 3104 patients with BE, and 2182 healthy individuals (controls)
participating in the Barrett’s and Esophageal Adenocarcinoma Consortium GWAS, the UKhip.
er: BE, Barrett’s esophagus; BMI, body
terval; EA, esophageal adenocarcinoma;
GERD, gastroesophageal reﬂux disease;
n study; MAF, minor allele frequency; OR,
ide polymorphism.
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177Barrett’s Esophagus Gene Study, and the UK Stomach and Oesophageal Cancer Study. We
analyzed 993,501 SNPs in DNA samples of all study subjects. We used standard case–control
logistic regression to test for gene-environment interactions.178
179RESULTS:
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183
184
185
186For EA, rs13429103 at chromosome 2p25.1, near the RNF144A-LOC339788 gene, showed a
borderline signiﬁcant interaction with smoking status (P ¼ 2.18310-7). Ever smoking was
associated with an almost 12-fold increase in risk of EA among individuals with rs13429103-AA
genotype (odds ratio[11.82; 95% CI, 4.03–34.67). Three SNPs (rs12465911, rs2341926,
rs13396805) at chromosome 2q23.3, near the RND3-RBM43 gene, interacted with GERD
symptoms (P[ 1.70310-7, P[ 1.83310-7, and P[ 3.58310-7, respectively) to affect risk of EA.
For BE, rs491603 at chromosome 1p34.3, near the EIF2C3 gene, and rs11631094 at chromo-
some 15q14, at the SLC12A6 gene, interacted with BMI (P [ 4.44310-7) and pack-years of
smoking history (P [ 2.82310-7), respectively.187
188
CONCLUSION:189
190The associations of BMI, smoking, and GERD symptoms with risks of EA and BE appear to
vary with SNPs at chromosomes 1, 2, and 15. Validation of these suggestive interactions
is warranted.191192
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232Over the past 4 decades, the incidence ofesophageal adenocarcinoma (EA) has increased
markedly in many Western populations. Among white
men in the United States the incidence has increased
almost 10-fold,1 and rates continue to rise by 2% per
year.2 EA is a highly fatal cancer with a median overall
survival of <1 year following diagnosis.3 EAs typically
arise on a background of a premalignant change in the
lining of the esophagus known as Barrett’s esophagus
(BE). Thus, proposals to prevent EA-associated morbidity
and mortality have suggested focusing on identifying
patients with BE and enrolling them in endoscopic sur-
veillance programs, or on identifying and modifying
risk factors for neoplastic progression.4–6
Epidemiologic studies have identiﬁed frequent or
persistent symptoms of gastroesophageal reﬂux disease
(GERD),7,8 obesity,9 and smoking10,11 as the principal
factors associated with increased risks of EA and BE.
These 3 factors together comprise almost 80% of the
attributable burden of EA.12,13 Genetic factors also
inﬂuence risk of EA and BE. Recent genome-wide asso-
ciation studies (GWAS) and post-GWAS studies have
identiﬁed more than 20 loci signiﬁcantly associated with
risks of EA and BE14; however, these variants seem to
explain only a limited proportion of the heritability of
these diseases (estimated to be 25% for EA and 35% for
BE).15 It is possible that environmental risk factors for
EA and BE may interact with multiple genes through
various biological pathways to contribute to disease
susceptibility. Given the strength of associations with
known risk factors for EA and BE (especially when
compared with most other cancers), and potentially
shared biological pathways (eg, inﬂammation) underly-
ing these risk factors,16 identifying gene-environment
interactions may be more plausible in the setting of EA
and BE. These gene-environment interactions may
account for some of the missing heritability of EA andFLA 5.5.0 DTD  YJCGH55745_proofBE.15 However, previous efforts to identify gene-
environment interactions for EA and BE have predomi-
nantly been candidate based and have involved only small
numbers of single nucleotide polymorphisms (SNPs).17–19
With the aim of identifying SNPs that may modify the
associations of body mass index (BMI), smoking, and
GERD symptoms with risks of EA and BE, we used pooled
questionnaire and genetic data from several studies to
conduct a large scale genome-wide gene-environment
interaction study of EA and BE.Methods
Study Population
We obtained data from 1512 EA patients, 2413 BE
patients, and 2185 control subjects of European ancestry
from 14 epidemiologic studies conducted in Western
Europe, Australia, and North America participating in
the International Barrett’s and Esophageal Adenocarci-
noma Consortium (http://beacon.tlvnet.net/) GWAS.
The design of the Barrett’s and Esophageal Adenocar-
cinoma Consortium GWAS has been described in detail
previously.20 Histological conﬁrmation of EA and BE
was carried out for all the participating studies. The
pooled dataset also included an additional 1,003 EA
patients and 882 BE patients from the United Kingdom
Stomach and Oesophageal Cancer Study and the UK
Barrett’s Esophagus Gene Study, respectively.20 The EA
patients in the UK Stomach and Oesophageal Cancer
Study had International Classiﬁcation of Diseases cod-
ing of malignant neoplasm of the esophagus (C15) and
pathological diagnosis of adenocarcinoma (M8140-
8575). The BE patients were identiﬁed at endoscopy
with conﬁrmed histopathological diagnosis of intestinal
metaplasia in the UK Barrett’s Esophagus Gene Study. 8 May 2018  8:04 pm  ce OB
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tional review board approval and all participants gave
informed consent.294
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308SNP Genotyping
Genotyping of buffy coat or whole blood DNA from all
participants was conducted using the Illumina Omni1M
Quad platform, in accordance with standard quality-
control procedures.21 For quality control, genotyped
SNPs were excluded based on call rate <95%, Hardy-
Weinberg Equilibrium P value over controls of <10–4,
or minor allele frequency (MAF) 2%. After quality
assurance and quality control, 993,501 SNPs were used
for the current analysis. The analysis was restricted to
the subset of ethnically homogenous individuals of
European ancestry (conﬁrmed in GWAS samples using
principal components analysis).20Q5
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348Environmental (“Exposure”) Variables
Individual-level exposure data for each study
participant were harmonized and merged into a single
deidentiﬁed dataset. The data were checked for
consistency and completeness and any apparent
inconsistencies were followed up with individual study
investigators. Depending on the study, data from
self-reported written questionnaires or in-person
interviews were obtained at or near the time of can-
cer diagnosis for EA patients, at or near the time of BE
diagnosis for BE patients, and at the time of recruitment
for control subjects. BMI was calculated as weight
divided by square of height (kg/m2). For the analysis
we selected the weight from each participant that likely
reﬂected usual adult weight (before, for example, any
disease-related weight loss). For tobacco smoking, the
exposure variables were smoking status (ever vs never)
and total cigarette smoking exposure among ever
smokers (pack-years of smoking exposure). Ever ciga-
rette smoking was deﬁned as either low threshold
exposure (100 cigarettes over their whole life) or by
asking whether they had ever smoked regularly. Pack-
years of smoking exposure was derived by dividing
the average number of cigarettes smoked daily by 20
and multiplying by the total number of years smoked.
GERD symptoms were deﬁned as the presence of
heartburn (ie, a burning or aching pain behind the
sternum) or acid reﬂux (ie, a sour taste from acid,
bile, or other stomach contents rising up into the
mouth). For analysis, we used the highest reported
frequency for either GERD symptom. Participants
were then categorized as recurrent vs not recurrent
based on a frequency of weekly or greater GERD
symptoms for “recurrent.”7 A total of 425 participants
with missing values for all 3 covariates (BMI, smoking
history, and history of GERD symptoms) were excluded
from the analysis.FLA 5.5.0 DTD  YJCGH55745_proofStatistical Analysis
We used standard case-control logistic regression to
test for gene-environment interactions. SNP genotypes
were treated as continuous variables and coded as 0, 1,
or 2 copies of the minor allele. Exposure variables were
either continuous (BMI and pack-years of smoking
exposure) or dichotomous (smoking status and GERD
symptoms). We modeled the gene-environment interac-
tion by the product of the SNP genotype and the expo-
sure variable, adjusting for age, sex, the ﬁrst 4 principal
components to control for possible population stratiﬁ-
cation, and the main terms of the SNP and the exposure
variable. We used model-robust standard errors as sug-
gested in Voorman et al22 to avoid inﬂated test statistics
that can arise due to underestimation of variability in
gene-environment GWAS. For SNPs from each of the top
gene-environment interaction hits (ie, main text, P value
for interaction <5.0  10–7) (Supplemental Material,
P value for interaction <1.0  10–6) we also performed
stratiﬁed analyses by genotype to examine the modiﬁed
association of the known risk factor for EA or BE within
the speciﬁc genotypes. Analyses were conducted using
R software (R Foundation for Statistical Computing,
Vienna, Austria), the GWASTools package,23 and Stata
13.0 (StataCorp LP, College Station, TX).
Results
The ﬁnal study sample included 2284 EA patients,
3104 BE patients, and 2182 control subjects. Charac-
teristics of the study sample are shown in Table 1. On
average, BMI was higher among EA (mean, 28.4 kg/m2)
and BE (mean, 28.7 kg/m2) patients than among control
subjects (mean, 27.0 kg/m2). Similarly, EA and BE
patients were more likely than control subjects to be
ever smokers (74.8%, 64.8%, and 59.1%, respectively)
and to report history of recurrent GERD symptoms
(46.9%, 52.9%, and 19.4%, respectively).
Gene-Environment Interactions for EA
For EA, at borderline genome-wide signiﬁcance, 1
SNP interacted with smoking status and 3 interacted
with recurrent GERD symptoms (P for interactions
ranging from 3.58  10–7 to 1.70  10–7) (Table 2,
Figure 1A and B). At chromosome 2p25.1, rs13429103
(effect allele frequency [EAF] ¼ 15.0%) showed
interaction with smoking status (RNF144A-LOC339788,
P ¼ 2.18  10–7 for interaction). We also observed
borderline statistically signiﬁcant interactions between
recurrent GERD symptoms and rs12465911 (P ¼ 1.70 
10–7 for interaction), rs2341926 (P ¼ 1.83  10–7 for
interaction), and rs13396805 (P ¼ 3.58  10–7 for
interaction) at chromosome 2q23.3 (RND3-RBM43).
These 3 SNPs are in high linkage disequilibrium (all
r2 > 0.9) as indicated in Figure 1B. Additional suggestive 8 May 2018  8:04 pm  ce OB
Table 1. Characteristics of the Study Population
Characteristic
Control Subjects
n ¼ 2182
EA
n ¼ 2284
Control Subjects vs EA
P valuea
BE
n ¼ 3104
Control Subjects vs BE
P Valuea
Age, y 61.7  11.1 65.1  10.3 <.001 62.9  12.1 <.001
Sex <.001 .008
Male 1715 (78.6) 1990 (87.1) 2343 (75.5)
Female 467 (21.4) 294 (12.9) 761 (24.5)
Body mass index, kg/m2 <.001 <.001
Mean 27.0  4.7 28.4  5.2 28.7  5.1
<25 786 (36.3) 245 (24.6) 608 (20.7)
25–29.99 944 (43.5) 455 (45.8) 1191 (42.8)
30 436 (20.2) 296 (29.6) 935 (36.5)
Missing 16 1288 370
Smoking status <.001 <.001
Never 888 (40.9) 568 (25.2) 1081 (35.2)
Ever 1282 (59.1) 1686 (74.8) 1994 (64.8)
Missing 12 30 29
Cumulative smoking
history, pack-yearsb
.43 .001
Mean 32.8  27.9 33.6  26.4 29.4  24.8
Recurrent GERD symptoms <.001 <.001
No 1446 (80.6) 965 (53.1) 1058 (47.1)
Yes 348 (19.4) 854 (46.9) 1186 (52.9)
Missing 388 465 860
NOTE. Values are mean  SD or n (%).
BE, Barrett’s esophagus; EA, esophageal adenocarcinoma; GERD, gastroesophageal reﬂux disease.
aP value from chi-square tests for categorical variables and Student’s t test for continuous variables. Missing categories were excluded from comparison tests.
bAmong ever smokers.
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447gene-environment interactions for EA (where P < 1.0 
10–6 for interaction) are shown in Supplemental Table 1.
In analyses stratiﬁed by genotype (Table 3),
compared with never smoking, ever smoking was asso-
ciated with nearly a 12-fold higher risk of EA among
individuals with rs13429103-AA genotype (odds ratio
[OR], 11.82; 95% conﬁdence interval [CI], 4.03–34.67).
In contrast, among individuals with rs13429103-GG ge-
notype, ever smoking conferred only 1.6-fold higher risk
of EA (OR, 1.59; 95% CI, 1.36–1.85). Similarly, the risk
for EA associated with recurrent GERD symptoms was
higher in individuals with rs12465911-AA genotype (OR,
13.12; 95% CI, 6.21–27.73) than among individuals withTable 2.Gene-Environment Interactions With EA or BE With a
Outcome Exposure SNP Chr Pos
EA
Smoking status rs13429103 2p25.1 751
Recurrent GERD symptoms rs12465911 2q23.3 15178
Recurrent GERD symptoms rs2341926 2q23.3 15178
Recurrent GERD symptoms rs13396805 2q23.3 15182
BE
BMI (continuous) rs491603 1p34.3 3653
Pack-years of smoking rs11631094 15q14 3462
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma
ratio; SNP, single nucleotide polymorphism.
FLA 5.5.0 DTD  YJCGH55745_proofrs12465911-GG genotype (OR, 2.80; 95% CI, 2.29–3.41).
Additional stratiﬁed analyses for risk of EA are shown in
Table 3 and Supplemental Table 2.Gene-Environment Interactions for BE
For BE, at chromosome 1p34.3, we observed an
interaction between rs491603 (EAF ¼ 16.5%) and
BMI (EIF2C3-LOC100128093, P ¼ 4.44  10–7 for
interaction) (Table 2, Figure 1C). At chromosome
15p14, rs11631094 (EAF ¼ 28.7%) showed interac-
tion with pack-years of smoking exposure (SLC12A6,P Value for Interaction <5.0  10–7
ition Gene
Effect/
Other EAF OR P
7231 RNF144A-LOC339788 A/G 0.15 2.04 2.18  10–7
5742 RND3-RBM43 A/G 0.26 2.03 1.70  10–7
3928 RND3-RBM43 C/T 0.26 2.02 1.83  10–7
1512 RND3-RBM43 A/G 0.26 1.99 3.58  10–7
2316 EIF2C3-LOC100128093 A/G 0.16 1.08 4.44  10–7
4438 SLC12A6 A/C 0.29 0.99 2.82  10–7
; EAF, effect allele frequency; GERD, gastroesophageal reﬂux disease; OR, odds
 8 May 2018  8:04 pm  ce OB
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Figure 1. Regional association plots for genotyped single nucleotide polymorphisms (SNPs) showing P values for interaction
for (A) smoking status and (B) recurrent gastroesophageal reﬂux disease symptoms in esophageal adenocarcinoma and (C)
body mass index and (D) pack-years of smoking exposure in Barrett’s esophagus. The SNPs in Table 2 are shown as a solid
purple diamond, except in panel B where rs2341926 and rs13396805 are shown as circles near rs12465911. The color scheme
indicates linkage disequilibrium between the SNP shown with a solid purple diamond and other SNPs in the region using the r2
value calculated from the 1000 Genomes Project. The y axis is the log10 interaction P value computed from 5388 cases
(3104 Barrett’s esophagus, 2284 esophageal adenocarcinoma) and 2182 control subjects. The recombination rate from CEU
HapMap data (right-side y axis) is shown in light blue. (A) Chromosome 2p25.1; (B) chromosome 2q23.3 region; (C) chro-
mosome 1p34.3 region; (D) chromosome 15q14 region.
- 2018 Gene-Environment Interactions and Esophageal Adenocarcinoma 5
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579P ¼ 2.82  10–7 for interaction) (Table 2, Figure 1D).
Additional suggestive signiﬁcant interactions (where
P < 1.0  10–6 for interaction) for BE with pack-years
of smoking exposure at chromosomes 12q23.1,
16p12.3, and 17q12 are presented in Supplemental
Table 1.
Stratiﬁed analyses by genotype showed that the risk
for BE associated with obesity (BMI 30 kg/m2) was
elevated by over 200% among individuals with
rs491603-AA genotype (vs BMI <25 kg/m2; OR, 3.30;
95% CI, 1.90–5.73) but only by approximately
50% among individuals with rs491603-GG genotype
(vs BMI <25 kg/m2; OR, 1.52; 95% CI, 1.38–1.67).
Additional stratiﬁed analyses of gene-environment
interactions for BE are shown in Table 3 and
Supplemental Table 2.FLA 5.5.0 DTD  YJCGH55745_proofCross-Examination of Discovered
Gene-Environment Interactions
For each SNP in Table 2 and Supplemental Table 1
that had a borderline signiﬁcant genome-wide interac-
tion in either EA or BE, we examined the equivalent
gene-environment interaction in BE and EA, respectively
(Supplemental Table 3). For all SNPs discovered in EA,
we observed nominal levels of signiﬁcance (P value for
interaction <.05) and ORs in the same direction but
somewhat attenuated in BE. For SNPs discovered in BE,
only half had P value for interaction <.05 in EA, although
all had similar ORs to those in BE. Although obesity and
GERD are correlated, none of the SNPs with P value for
interaction <1.0  10–6 with GERD had comparable ORs 8 May 2018  8:04 pm  ce OB
580
Table 3. Risk of EA and BE in Association With Obesity, Smoking History and Recurrent GERD Symptoms, Stratiﬁed by
Genotype for SNPs in Table 2
Outcome
Environmental
Exposure SNP Genotype
Cases/Control
Subjects OR 95% CI
P
Valuea
EA
Ever smoker vs never smoker (ref) rs13429103 GG 1617/1572 1.59 1.36–1.85 <.001
GA 589/554 2.91 2.23–3.81 <.001
AA 48/44 11.82 4.03–34.67 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs12465911 GG 1206/1196 2.80 2.29–3.41 <.001
GA 885/823 5.32 4.10–6.90 <.001
AA 163/151 13.12 6.21–27.73 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2341926 TT 975/985 2.80 2.30–3.42 <.001
TC 724/681 5.30 4.08–6.88 <.001
CC 120/128 13.12 6.21–27.73 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs13396805 GG 998/1005 2.85 2.34–3.48 <.001
GA 701/662 5.23 4.02–6.81 <.001
AA 120/127 12.73 6.12–26.49 <.001
BE
BMI 30 kg/m2 vs BMI <25 kg/m2 (ref) rs491603 GG 1306/1137 1.52 1.38–1.67 <.001
GA 438/518 2.11 1.80–2.47 <.001
AA 42/64 3.30 1.90–5.73 <.001
15 pack-years vs <15 pack-years (ref) rs11631094 CC 729/618 1.02 0.81–1.30 .846
CA 555/540 0.65 0.50–0.84 .001
AA 115/106 0.52 0.28–0.95 .033
BE, Barrett’s esophagus; BMI, body mass index; CI, conﬁdence interval; EA, esophageal adenocarcinoma; GERD, gastroesophageal reﬂux disease; OR, odds
ratio; SNP ¼ single nucleotide polymorphism.
aP values from logistic regression analysis adjusted for age and sex.
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696or P values when testing for interaction with obesity and
similarly for the 1 obesity SNP when tested for GERD.
Discussion
To our knowledge, this is the ﬁrst genome-wide
gene-environment interaction study of EA and its pre-
cursor, BE. Although no gene-environment interactions
reached genome-wide signiﬁcance (ie, P < 5.0  10–8 for
interaction), several borderline signiﬁcant interactions
were indicated between SNPs and known risk factors for
EA and BE – BMI, smoking, and GERD symptoms.
A number of studies have pursued candidate-based
gene-environment analyses of EA, and reported in-
teractions between BMI, smoking or GERD symptoms
and selected SNPs in genes related to detoxiﬁcation,
angiogenesis, DNA repair, apoptosis, and extracellular
matrix degradation.24–31 This body of work helped to
establish the notion that the level of disease risk asso-
ciated with GERD symptoms, in particular, may vary
according to inherited genetic variation. All of these
studies, however, were conducted in small samples
(<350 cases) and were not replicated in independent
populations. While direct comparison of our own results
and these past ﬁndings is complicated by less-than-
complete overlap of genotyped SNPs between studies,
we did not ﬁnd evidence in support of interactions
among BMI, smoking, or GERD symptoms and anyFLA 5.5.0 DTD  YJCGH55745_proofassessed variants in previously-implicated genes: GSTM1,
GSTT1, VEGF, MGMT, EGF, IL1B, PERP, PIK3CA,
TNFRSF1A, CASP7, TP53BP1, BCL2, HIF1AN, PDGRFA,
VEGFR1, or MMP1 (Supplemental Table 4). It remains
possible that nominal evidence for some of these asso-
ciations may not have survived stringent correction for
multiple comparisons, and larger samples are needed for
true signals to reach signiﬁcance. Alternatively, previ-
ously reported interactions may simply reﬂect chance
ﬁndings in small samples because they did not validate
in our large study population.
This study has several strengths. First, the pooled
dataset including relatively large numbers of cases and
control subjects provided us with a rare opportunity to
perform, in parallel, genome-wide gene-environment
interaction analyses for EA and its precursor lesion, BE.
Past candidate-based gene-environment interaction
studies of EA have focused on small numbers of genes
selected according to biological plausibility, and collec-
tively these reports sampled only a small fraction of
the total SNPs presently analyzed (N ¼ 993,501). Such
preconceived “gene-centric” SNP selection methods fail
to capture the large fraction of noncoding intergenic
variations that have been linked to altered risk for these
2 conditions, and also artiﬁcially restricts the “genic”
search space based on limited mechanistic knowledge,
a limitation that is overcome by an unbiased compre-
hensive genome-wide gene-environment interaction 8 May 2018  8:04 pm  ce OB
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812assessment. Second, our study draws on genetic and
epidemiologic data from a recent consortium-based
GWAS of EA/BE,20 which is the largest of its kind. This
sizable study sample afforded greater power to detect
gene-environment interactions than in any previous
study. Third, all genotyping from this GWAS was con-
ducted on a single platform and in a single laboratory,
and subjected to stringent quality-control procedures.
Most GWAS analyses test only an additive model because
an additive model has reasonable power to detect both
additive and dominant effects and the 2 models yield
similar results and many GWAS analyses, including
ours, are underpowered to detect recessive effects.
Nevertheless, for completeness we also tested a domi-
nant model for the 16 SNPs with a P value for interaction
<1.0  10–6 (Table 2 and Supplemental Table 1), and
found slightly attenuated results of the ORs for some
gene-environment interactions (data not shown).
Our study also has some limitations. First, our ability
to detect true gene-environment interactions might have
been limited by the manner in which the environmental
(exposure) variables were measured and harmonized.
For example, recall bias is a possibility during retro-
spective reporting of the exposures in the parent case-
control studies. However, respondents were unaware of
their genotype status at the time of the interviews,
mitigating the impact of any possible recall bias in our
interaction analyses. Similarly, while considerable care
was taken during data harmonization, as described in a
series of recent pooled analyses,10,11 some potential for
measurement error of the exposures examined is
possible. However, given that case-control status was not
considered during this process, any errors from harmo-
nization would be nondifferential, resulting in attenua-
tion of the resulting ORs. Second, central obesity
(eg, waist-to-hip ratio) has been found to be more
strongly associated with the risk of BE than BMI;
however, as waist and hip measurements were not
collected in the majority of the included studies, we were
unable to examine for interactions with central obesity.
Third, despite the comprehensive nature of the genome-
wide analysis, we were nonetheless limited to examining
common genetic variation (MAF >2%) represented on
the Illumina Omni1M Quad GWAS platform employed.
Further large-scale studies based on whole-exome or
whole-genome sequencing would be required to identify
additional gene-environment interactions with rare
variants, and more precisely map the reported associa-
tions. Finally, our study results should be considered as
discovery ﬁndings, worthy of independent replication.
None of the interactions studied reached genome-wide
signiﬁcance (ie, P < 5.0  10–8 for interaction). This
may be because there are truly no gene-environment
interactions or it may be that power was still limited to
detect modest or weak interactions despite our large
sample size. In our analyses of 2284 EA patients, 3104
BE patients, and 2182 control subjects, we were
adequately powered to detect interactions with anFLA 5.5.0 DTD  YJCGH55745_proofinteraction OR in the range of 1.98–2.52 for MAF in the
observed range (0.11–0.43), assuming a main effect of
1.08 for log-additive SNPs, a main effect of 1.90 for
binary risk factors, and an a of 5.0  10–8. Given the
large worldwide consortia sample of patients partici-
pating in this work, few additional studies of EA and BE
patients are currently available and have data for repli-
cation; thus, such work may require additional time for
study patients to accrue.
In conclusion, our report describes the ﬁrst genome-
wide gene-environment interaction analysis for EA and
BE. These ﬁndings provide evidence that the magnitude
of disease risk associated with BMI, smoking, and GERD
symptoms may differ according to germline genetics,
and suggest the potential utility of combing epidemio-
logic exposure data with selected genotyping for
comprehensive risk assessment in patients susceptible
to EA or BE. Pending validation of the observed
interactions in independent study populations, further
analyses will be required to investigate the biological
basis for differential disease risk associated with the
risk factors investigated in the presence of these
variants.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
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and at https://doi.org/10.1016/j.cgh.2018.03.007. 8 MReferences
1. Vaughan TL, Fitzgerald RC. Precision prevention of oesopha-
geal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015;
12:243–248.
2. Thrift AP, Whiteman DC. The incidence of esophageal adeno-
carcinoma continues to rise: analysis of period and birth cohort
effects on recent trends. Ann Oncol 2012;23:3155–3162.
3. Thrift AP. The epidemic of oesophageal carcinoma: Where are
we now? Cancer Epidemiol 2016;41:88–95.
4. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline:
Diagnosis and management of Barrett’s esophagus. Am J
Gastroenterol 2016;111:30–50.
5. Spechler SJ, Sharma P, Souza RF, et al. American Gastroen-
terological Association technical review on the management of
Barrett’s esophagus. Gastroenterology 2011;140:e18–e52.
6. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of
Gastroenterology guidelines on the diagnosis and management
of Barrett’s oesophagus. Gut 2014;63:7–42.
7. Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reﬂux
in relation to adenocarcinomas of the esophagus: a pooled
analysis from the Barrett’s and Esophageal Adenocarcinoma
Consortium (BEACON). PLoS One 2014;9:e103508.
8. Thrift AP, Kramer JR, Qureshi Z, et al. Age at onset of GERD
symptoms predicts risk of Barrett’s esophagus. Am J Gastro-
enterol 2013;108:915–922.
9. Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and risk of
esophageal adenocarcinoma and Barrett’s esophagus: a Men-
delian randomization study. J Natl Cancer Inst 2014;106:dju252.ay 2018  8:04 pm  ce OB
Q8
Q2
8 Dong et al Clinical Gastroenterology and Hepatology Vol. -, No. -
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
92610. Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking
and adenocarcinomas of the esophagus and esophagogastric
junction: a pooled analysis from the international BEACON
consortium. J Natl Cancer Inst 2010;102:1344–1353.
11. Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking
increases risk of Barrett’s esophagus: an analysis of the
Barrett’s and Esophageal Adenocarcinoma Consortium.
Gastroenterology 2012;142:744–753.
12. Olsen CM, Pandeya N, Green AC, et al. Population attributable
fractions of adenocarcinoma of the esophagus and gastro-
esophageal junction. Am J Epidemiol 2011;174:582–590.
13. Engel LS, Chow WH, Vaughan TL, et al. Population attributable
risks of esophageal and gastric cancers. J Natl Cancer Inst
2003;95:1404–1413.
14. Contino G, Vaughan TL, Whiteman D, et al. The evolving
genomic landscape of Barrett’s esophagus and esophageal
adenocarcinoma. Gastroenterology 2017;153:657–673.
15. Ek WE, Levine DM, D’Amato M, et al. Germline genetic contri-
butions to risk for esophageal adenocarcinoma, Barrett’s
esophagus, and gastroesophageal reﬂux. J Natl Cancer Inst
2013;105:1711–1718.
16. Buas MF, He Q, Johnson LG, et al. Germline variation in
inﬂammation-related pathways and risk of Barrett’s oesophagus
and oesophageal adenocarcinoma. Gut 2017;66:1739–1747.
17. Dai JY, de Dieu Tapsoba J, Buas MF, et al. A newly identiﬁed
susceptibility locus near FOXP1 modiﬁes the association of
gastroesophageal reﬂux with Barrett’s esophagus. Cancer
Epidemiol Biomarkers Prev 2015;24:1739–1747.
18. Matejcic M, Iqbal Parker M. Gene-environment interactions in
esophageal cancer. Crit Rev Clin Lab Sci 2015;52:211–231.
19. Zhang L, Jiang Y, Wu Q, et al. Gene-environment interactions on
the risk of esophageal cancer among Asian populations with the
G48A polymorphism in the alcohol dehydrogenase-2 gene: a
meta-analysis. Tumour Biol 2014;35:4705–4717.
20. Levine DM, Ek WE, Zhang R, et al. A genome-wide association
study identiﬁes new susceptibility loci for esophageal adeno-
carcinoma and Barrett’s esophagus. Nat Genet 2013;
45:1487–1493.
21. Laurie CC, Doheny KF, Mirel DB, et al. Quality control and
quality assurance in genotypic data for genome-wide associa-
tion studies. Genet Epidemiol 2010;34:591–602.
22. Voorman A, Lumley T, McKnight B, et al. Behavior of QQ-plots
and genomic control in studies of gene-environment interac-
tion. PLoS One 2011;6:e19416.
23. Gogarten SM, Bhangale T, Conomos MP, et al. GWASTools: an
R/Bioconductor package for quality control and analysis of
genome-wide association studies. Bioinformatics 2012;
28:3329–3331.
24. Casson AG, Zheng Z, Porter GA, et al. Genetic polymorphisms of
microsomal epoxide hydroxylase and glutathione S-transferases
M1, T1 and P1, interactions with smoking, and risk for
esophageal (Barrett) adenocarcinoma. Cancer Detect Prev
2006;30:423–431.
25. Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of
VEGF, interactions with cigarette smoking exposure and
esophageal adenocarcinoma risk. Carcinogenesis 2008;
29:2330–2334.
26. Doecke J, Zhao ZZ, Pandeya N, et al. Polymorphisms in MGMT
and DNA repair genes and the risk of esophageal adenocarci-
noma. Int J Cancer 2008;123:174–180.FLA 5.5.0 DTD  YJCGH55745_proof27. Cheung WY, Zhai R, Kulke MH, et al. Epidermal growth factor
A61G gene polymorphism, gastroesophageal reﬂux disease and
esophageal adenocarcinoma risk. Carcinogenesis 2009;
30:1363–1367.
28. Zhai R, Chen F, Liu G, et al. Interactions among genetic
variants in apoptosis pathway genes, reﬂux symptoms, body
mass index, and smoking indicate two distinct etiologic
patterns of esophageal adenocarcinoma. J Clin Oncol 2010;
28:2445–2451.
29. Wu IC, Zhao Y, Zhai R, et al. Interactions between genetic
polymorphisms in the apoptotic pathway and environmental
factors on esophageal adenocarcinoma risk. Carcinogenesis
2011;32:502–506.
30. Zhai R, Zhao Y, Liu G, et al. Interactions between environmental
factors and polymorphisms in angiogenesis pathway genes in
esophageal adenocarcinoma risk: a case-only study. Cancer
2012;118:804–811.
31. Cheung WY, Zhai R, Bradbury P, et al. Single nucleotide
polymorphisms in the matrix metalloproteinase gene family and
the frequency and duration of gastroesophageal reﬂux disease
inﬂuence the risk of esophageal adenocarcinoma. Int J Cancer
2012;131:2478–2486.
Reprint requests
Address requests for reprints to: Aaron P. Thrift, PhD, Dan L. Duncan
Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza,
Houston, Texas 77030-3498. e-mail: aaron.thrift@bcm.edu.
Acknowledgments
The following UK hospitals participated in sample collection through the
Stomach and Oesophageal Cancer Study (SOCS) collaboration network:
Addenbrooke’s Hospital, University College London, Bedford Hospital, Hin-
chingbrooke Hospital, Peterborough City Hospital, West Suffolk Hospital,
Norfolk and Norwich University Hospital, Churchill Hospital, John Radcliffe
Hospital, Velindre Hospital, St Bartholomew’s Hospital, Queen’s Hospital
Burton, Queen Elisabeth Hospital, Diana Princess of Wales, Scunthorpe
General Hospital, Royal Devon & Exeter Hospital, New Cross Hospital, Belfast
City Hospital, Good Hope Hospital, Heartlands Hospital, South Tyneside Dis-
trict General Hospital, Cumberland Inﬁrmary, West Cumberland Hospital,
Withybush General Hospital, Stoke Mandeville Hospital, Wycombe General
Hospital, Wexham Park Hospital, Southend Hospital, Guy’s Hospital, South-
ampton General Hospital, Bronglais General Hospital, Aberdeen Royal In-
ﬁrmary, Manor Hospital, Clatterbridge Centre for Oncology, Lincoln County
Hospital, Pilgrim Hospital, Grantham & District Hospital, St Mary’s Hospital
London, Croydon University Hospital, Whipps Cross University Hospital,
Wansbeck General Hospital, Hillingdon Hospital, Milton Keynes General Hos-
pital, Royal Gwent Hospital, Tameside General Hospital, Castle Hill Hospital, St
Richard’s Hospital, Ipswich Hospital, St Helens Hospital, Whiston Hospital,
Countess of Chester Hospital, St Mary’s Hospital IOW, Queen Alexandra
Hospital, Glan Clwyd Hospital, Wrexham Maelor Hospital, Darent Valley Hos-
pital, Royal Derby Hospital, Derbyshire Royal Inﬁrmary, Scarborough General
Hospital, Kettering General Hospital, Kidderminster General Hospital, Royal
Lancaster Inﬁrmary, Furness General Hospital, Westmorland General Hospital,
James Cook University Hospital, Friarage Hospital, Stepping Hill Hospital, St
George’s Hospital London, Doncaster Royal Inﬁrmary, Maidstone Hospital,
Tunbridge Hospital, Prince Charles Hospital, Hartlepool Hospital, University
Hospital of North Tees, Ysbyty Gwynedd, St. Jame’s University Hospital,
Leeds General Inﬁrmary, North Hampshire Hospital, Royal Preston Hospital,
Chorley and District General, Airedale General Hospital, Huddersﬁeld Royal
Inﬁrmary, Calderdale Royal Hospital, Torbay District General Hospital, Leighton
Hospital, Royal Albert Edward Inﬁrmary, Royal Surrey County Hospital, Brad-
ford Royal Inﬁrmary, Burnley General Hospital, Royal Blackburn Hospital, Royal
Sussex County Hospital, Freeman Hospital, Royal Victoria Inﬁrmary, Victoria
Hospital Blackpool, Weston Park Hospital, Royal Hampshire County Hospital,
Conquest Hospital, Royal Bournemouth General Hospital, Mount Vernon
Hospital, Lister Hospital, William Harvey Hospital, Kent and Canterbury Hos-
pital, Great Western Hospital, Dumfries and Galloway Royal Inﬁrmary, Poole
General Hospital, St Hellier Hospital, North Devon District Hospital, Salisbury
District Hospital, Weston General Hospital, University Hospital Coventry,
Warwick Hospital, George Eliot Hospital, Alexandra Hospital, Nottingham
University Hospital, Royal Chesterﬁeld Hospital, Yeovil District Hospital, Dar-
lington Memorial Hospital, University Hospital of North Durham, Bishop
Auckland General Hospital, Musgrove Park Hospital, Rochdale Inﬁrmary, North
Manchester General, Altnagelvin Area Hospital, Dorset County Hospital, James 8 May 2018  8:04 pm  ce OB
927
928
- 2018 Gene-Environment Interactions and Esophageal Adenocarcinoma 9
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005Paget Hospital, Derriford Hospital, Newham General Hospital, Ealing Hospital,
Pinderﬁelds General Hospital, Clayton Hospital, Dewsbury & District Hospital,
Pontefract General Inﬁrmary, Worthing Hospital, Macclesﬁeld Hospital, Uni-
versity Hospital of North Staffordshire, Salford Royal Hospital, Royal Shrews-
bury Hospital, Manchester Royal Inﬁrmary.
Conﬂicts of interest
The authors disclose no conﬂicts.
Funding
This work was supported by funding from the U.S. National Cancer Institute
(NCI) at the National Institutes of Health (grant number R01CA136725) (to
T.L.V. and D.C.W.). The U.S. Multi-Center Study was funded by grants U01-
CA57949 (to T.L.V.), U01-CA57983 (to M.D.G.), and U01-CA57923 (to
H.A.R.). The Seattle Barrett’s Esophagus Study was supported by P01 CA
91955 (to B.J.R.) from the NCI. The Australian Cancer Study was supported
by the Queensland Cancer Fund and the National Health and Medical
Research Council (NHMRC) of Australia (Program no. 199600) (to D.C.W,
Adele C. Green, Nicholas K. Hayward, Peter G. Parsons, David M. Purdie,
and Penelope M. Webb). The Swedish Esophageal Cancer Study was sup-
ported by grant R01 CA57947-03 (to Olof Nyren and Hans-Olov Adami) from
the NCI. The Los Angeles County Multi-ethnic Case-control Study was
supported by grants 3RT-0122 (Smoking and Risk of Proximal Vs. Distal
Gastric Cancer) (to A.H.W) and 10RT-0251 (Smoking, microsatellite instability
& gastric cancers) (to A.H.W) from the California Tobacco Related Research
Program and grant CA59636 (to L.B.) from the NCI. The FINBAR (Factors
Inﬂuencing the Barrett’s Adenocarcinoma Relationship) study was supportedFLA 5.5.0 DTD  YJCGH55745_proofby an Ireland-Northern Ireland Co-operation Research Project Grant spon-
sored by the Northern Ireland Research & Development Ofﬁce, and the Health
Research Board, Ireland (All-Ireland case-control study of Oesophageal
Adenocarcinoma and Barrett’s Oesophagus) (to Liam Murray and Harry
Comber). Additional funding was provided by the Ulster Cancer Foundation
(Belfast, Northern Ireland) and the Northern Ireland Research and Develop-
ment Ofﬁce Clinical Fellowship. The Study of Digestive Health was supported
by grant 5 RO1 CA 001833-02 (to D.C.W, Adele C. Green, Nicholas K.
Hayward, Peter G. Parsons, Sandra J. Pavey, David M. Purdie, Penelope M.
Webb, David Gotley, B. Mark Smithers, Glyn G. Jamieson, Paul Drew, David I.
Watson, and Andrew Clouston) from the NCI. The Study of Reﬂux Disease
was supported by grant R01 CA72866 (to T.L.V and Diana Farrow) from the
NCI. The UK Barrett’s Oesophagus Gene Study was supported by a Medical
Research Council Programme grant. The UK Stomach and Oesophageal
Cancer Study was funded by Cancer Research UK, as well as by funding
from the Cambridge National Institute of Health Research Biomedical
Research Centre and the Cambridge Experimental Cancer Medicine Centre.
D.A.C. was supported by RO1 DK63616-01, and R21 DK077742. N.J.S. is
supported by P30 DK034987 from the National Institutes of Health. T.L.V. is
supported by an Established Investigator Award (K05CA124911) from the
NCI. DCW is supported by a Research Fellowship from the NHMRC. S.M. is
supported by Australian Research Council and NHMRC Fellowships. This
work was supported by Roswell Park Cancer Institute and NCI grant
P30CA016056 (M.F.B.). J.D. is supported by a Research Training Grant from
the Cancer Prevention and Research Institute of Texas (CPRIT) (RP160097).
The funders of the individual studies had no role in the design, analysis, or
interpretation of the data, or in writing or publication decisions related to
this manuscript. 8 May 2018  8:04 pm  ce OB
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
Supplemental Table 1.Gene-Environment Interactions With EA or BE With a P Value for Interaction <1.0  10–6
Outcome Exposure SNP Chr Position Gene
Effect/
Other EAF OR P Value
EA
Smoking status rs2434584 5q11.2 57566073 ACTBL2-PLK2 C/T 0.08 2.52 7.44  10–7
Smoking status rs40210 5q11.2 57619964 ACTBL2-PLK2 A/G 0.08 2.46 8.82  10–7
Pack-years of smoking rs17002540 Xq27.1 139946061 CDR1-SPANXB2 T/C 0.19 0.99 5.92  10–7
Recurrent GERD symptoms rs2971030 7p21.3 10006341 LOC340268 G/A 0.42 1.77 6.02  10–7
Recurrent GERD symptoms rs7141987 14q32.31 101492224 SNORD114-31-
LOC100130814
G/A 0.42 1.77 7.11  10–7
Recurrent GERD symptoms rs2971028 7p21.3 10007255 LOC340268 A/G 0.40 1.76 8.56  10–7
BE
Pack-years of smoking rs9668109 12q23.1 99011272 IKIP A/G 0.09 0.98 6.31  10–7
Pack-years of smoking rs1548445 16p12.3 19691583 C16orf62 G/A 0.06 1.02 8.21  10–7
Pack-years of smoking rs2671828 17q12 33731764 SLFN11-LOC729839 A/G 0.43 0.99 9.54  10–7
Pack-years of smoking rs10507102 12q23.1 98990871 SLC25A3 A/G 0.09 0.98 9.91  10–7
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, gastroesophageal reﬂux disease; OR, odds
ratio; SNP, single nucleotide polymorphism.
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Supplemental Table 2. Risk of EA and BE in Association With Smoking History and GERD Symptoms, Stratiﬁed by Genotype
for SNPs in Supplemental Table 1
Outcome
Environmental
Exposure SNP Genotype
Cases/Control
Subjects OR 95% CI
P
Valuea
EA
Ever smoker vs never smoker (ref) rs2434584 TT 1907/1826 1.67 1.45–1.93 <.001
CT 342/328 4.33 3.00–6.24 <.001
CC 5/15 NA - -
Ever smoker vs never smoker (ref) rs40210 GG 1903/1821 1.67 1.45–1.92 <.001
GA 344/332 4.24 2.96–6.06 <.001
AA 6/16 NA - -
15 pack-years vs <15 pack-years (ref) rs17002540 CC 1053/1003 1.36 1.12–1.66 .002
CT 48/55 0.78 0.33–1.86 .579
TT 218/206 0.63 0.39–1.00 .052
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2971030 AA 599/603 2.68 2.08–3.44 <.001
GA 908/895 3.81 3.06–4.75 <.001
GG 309/293 9.44 6.17–14.45 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs7141987 AA 591/590 2.69 2.08–3.49 <.001
GA 908/887 3.74 3.02–4.64 <.001
GG 319/317 9.32 6.04–14.36 <.001
Recurrent GERD symptoms vs
nonrecurrent GERD symptoms (ref)
rs2971028 GG 625/635 2.70 2.11–3.45 <.001
GA 900/890 3.87 3.10–4.82 <.001
AA 294/268 9.58 6.17–14.88 <.001
BE
15 pack-years vs <15 pack-years (ref) rs9668109 GG 1167/1058 0.92 0.77–1.11 .390
GA 221/201 0.38 0.25–0.60 <.001
AA 11/5 0.33 0.02–5.64 .443
15 pack-years vs <15 pack-years (ref) rs1548445 AA 1223/1097 0.76 0.63–0.91 .002
GA 170/164 1.11 0.68–1.80 .675
GG 6/3 NA - -
15 pack-years vs <15 pack-years (ref) rs2671828 GG 457/423 0.93 0.70–1.23 .595
GA 688/588 0.84 0.66–1.07 .163
AA 246/250 0.54 0.36–0.80 .002
15 pack-years vs <15 pack-years (ref) rs10507102 GG 1166/1058 0.93 0.77–1.11 .409
GA 222/200 0.38 0.24–0.59 <.001
AA 11/5 0.33 0.02–5.64 .443
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; GERD, gastroesophageal reﬂux disease; SNP,
single nucleotide polymorphism.
aP values from logistic regression analysis adjusted for age and sex.
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Supplemental Table 3. Comparison of Gene-Environment Interactions in BE and EA for SNPs With P Value for Interaction
<1.0  10–6 on the Outcomes
Exposure SNP Chr Position Gene
Effect/
Other
BE EA
OR P OR P
G  E hits for EA
Smoking status rs13429103 2p25.1 7517231 RNF144A-LOC339788 A/G 1.40 3.51  10–3 2.04a 2.18  10–7
Smoking status rs2434584 5q11.2 57566073 ACTBL2-PLK2 C/T 1.56 3.90  10–3 2.52a 7.44  10–7
Smoking status rs40210 5q11.2 57619964 ACTBL2-PLK2 A/G 1.54 4.94  10–3 2.46a 8.82  10–7
Pack-years of smoking rs17002540 Xq27.1 139946061 CDR1-SPANXB2 T/C 0.99 4.83  10–3 0.99a 5.92  10–7
Recurrent GERD symptoms rs12465911 2q23.3 151785742 RND3-RBM43 A/G 1.66 6.09  10–5 2.03a 1.70  10–7
Recurrent GERD symptoms rs2341926 2q23.3 151783928 RND3-RBM43 C/T 1.65 7.38  10–5 2.02a 1.83  10–7
Recurrent GERD symptoms rs13396805 2q23.3 151821512 RND3-RBM43 A/G 1.59 2.80  10–4 1.99a 3.58  10–7
Recurrent GERD symptoms rs2971030 7p21.3 10006341 LOC340268 G/A 1.36 5.03  10–3 1.77a 6.02  10–7
Recurrent GERD symptoms rs7141987 14q32.31 101492224 SNORD114-31-
LOC100130814
G/A 1.29 1.40  10–2 1.77a 7.11  10–7
Recurrent GERD symptoms rs2971028 7p21.3 10007255 LOC340268 A/G 1.35 6.10  10–3 1.76a 8.56  10–7
G  E hits for BE
BMI (continuous) rs491603 1p34.3 36532316 EIF2C3-LOC100128093 A/G 1.08a 4.44  10–7 1.04 1.83  10–2
Pack-years of smoking rs11631094 15q14 34624438 SLC12A6 A/C 0.99a 2.82  10–7 1.00 0.125
Pack-years of smoking rs9668109 12q23.1 99011272 IKIP A/G 0.98a 6.31  10–7 0.99 9.74  10–3
Pack-years of smoking rs1548445 16p12.3 19691583 C16orf62 G/A 1.02a 8.21  10–7 1.01 9.70  10–2
Pack-years of smoking rs2671828 17q12 33731764 SLFN11-LOC729839 A/G 0.99a 9.54  10–7 1.00 6.13  10–2
Pack-years of smoking rs10507102 12q23.1 98990871 SLC25A3 A/G 0.98a 9.91  10–7 0.99 6.93  10–3
BE, Barrett’s esophagus; BMI, body mass index; EA, esophageal adenocarcinoma; EAF, effect allele frequency; G  E, gene-environment; GERD, gastro-
esophageal reﬂux disease; OR, odds ratio; SNP, single nucleotide polymorphism.
aOutcomes Q6.
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Supplemental Table 4. Associations of Previously Reported Gene-Environment Interactions With Esophageal
Adenocarcinoma in Our Study Population
Original Publication Current Study
Author SNP Exposure P Value
Directly Genotyped
or High-LD SNP P Value
Casson et al, 200624 NA - - - -
Zhai et al, 200825 rs833061 Smoking .03 rs833070 .068
Doecke et al, 200826 rs12269324 GERD symptoms - Direct .979
rs12268840 GERD symptoms - Direct .714
Cheung et al, 200927 rs4444903 GERD symptoms <.001a Direct .240
Zhai et al, 201228 rs1143634 GERD symptoms .008 Direct .398
rs1052486 BMI þ Smoking - - -
rs1052486 BMI - Direct .423
rs1052486 Smoking - Direct .532
Wu et al, 201129 rs648802 GERD symptoms .02 Direct .838
rs4855094 GERD symptoms .04 Direct .872
rs7644468 GERD symptoms .04 - -
rs4149579 GERD symptoms .04 - -
rs560191 Smoking .02 Direct .331
rs7907519 Smoking .04 rs11196449 .868
rs12454712 Smoking .04 Direct .435
Zhai et al, 201230 rs2295778 GERD symptoms .0005 rs12780796 .654
rs13337626 GERD symptoms .0067 rs34197769 .315
rs2295778 Smoking .004 - -
rs2296188 Smoking .014 Direct .905
rs2114039 BMI .0026 Direct .228
rs2296188 BMI .0023 Direct .452
rs11941492 BMI .013 Direct NAb
rs17708574 BMI .013 Direct .316
rs7324547 BMI .008 - -
rs17619601 BMI .016 - -
rs17625898 BMI .023 - -
Cheung et al, 201231 rs1799750 GERD symptoms .002 - -
rs3025058 GERD symptoms .04 - -
BMI, body mass index; GERD, gastroesophageal reﬂux disease; LD, linkage disequilibrium; SNP, single nucleotide polymorphism.
aTwo-way interaction.
bOn array but quality control failure. We were unable to validate all SNPs as some were biallelic or we failed to identify a high LD SNP (r2 < 0.70).
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